ASCO 2023 | SCORE: multisite randomised controlled trial evaluating shared care for colorectal cancer survivors

Michael Jefford, MBBS, PhD, FRACP, Peter MacCallum Cancer Centre, Melbourne, Australia, provides an overview of the SCORE study aimed to compare shared follow-up care (SC) with usual care (UC) for colorectal cancer (CRC) survivors. The primary objective was to assess the effect of SC on the EORTC QLQ-C30 Global Health Status/Quality of Life (GHQ-QoL) scale up to 12 months. Secondary objectives included evaluating QoL, patient perceptions of care, costs, clinical care processes, and feasibility. Participants were randomized to SC or UC, with SC replacing two oncologist visits with primary care provider (PCP) visits. The study found that SC was non-inferior to UC in terms of QoL and showed higher adherence to CEA testing. Participants exposed to SC preferred this model of follow-up care. Cost and implementation analyses will be conducted.This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.